BMI Adjusted Body Weight Calculator

Estimate ideal body weight, adjusted body weight, lean body weight, and BMI for obesity-aware dosing and clinical weight planning.

Share this calculator

X Facebook LinkedIn

Formula

ABW = IBW + AF x (Actual Weight - IBW)

Where ABW = Adjusted Body Weight, IBW = Ideal Body Weight (Devine formula: males 50 + 2.3 per inch over 60 inches, females 45.5 + 2.3 per inch over 60 inches), AF = Adjustment Factor (typically 0.4), and Actual Weight = patient measured weight in kilograms.

Worked Examples

Example 1: Obese Male Patient Drug Dosing

Problem: A 55-year-old male weighing 120 kg, height 170 cm, needs gentamicin dosing. Calculate IBW, ABW (factor 0.4), and BMI.

Solution: Height in inches = 170 / 2.54 = 66.9 inches\nInches over 60 = 6.9\nIBW (male) = 50 + 2.3 x 6.9 = 50 + 15.9 = 65.9 kg\nExcess weight = 120 - 65.9 = 54.1 kg\nABW = 65.9 + 0.4 x 54.1 = 65.9 + 21.6 = 87.5 kg\nBMI = 120 / (1.70)^2 = 120 / 2.89 = 41.5

Result: IBW: 65.9 kg | ABW: 87.5 kg | BMI: 41.5 (Class III Obesity). Dose gentamicin using ABW of 87.5 kg.

Example 2: Overweight Female Vancomycin Dosing

Problem: A 40-year-old female weighing 90 kg, height 165 cm. Calculate appropriate dosing weights for vancomycin and amikacin.

Solution: Height in inches = 165 / 2.54 = 64.96 inches\nInches over 60 = 4.96\nIBW (female) = 45.5 + 2.3 x 4.96 = 45.5 + 11.4 = 56.9 kg\nABW = 56.9 + 0.4 x (90 - 56.9) = 56.9 + 13.2 = 70.1 kg\nBMI = 90 / (1.65)^2 = 90 / 2.72 = 33.1

Result: Vancomycin: use actual weight 90 kg | Amikacin: use ABW 70.1 kg | BMI: 33.1 (Class I Obesity)

Example 3: Devine BJ - Gentamicin therapy, Drug Intelligence and Clinical Pharmacy

Problem: A male patient weighs 120 kg, is 170 cm tall, and the protocol uses an adjustment factor of 0.4. Which weight values should you compare?

Solution: Enter the measured weight, height, sex, and adjustment factor. The calculator estimates BMI, ideal body weight, adjusted body weight, and lean body weight so you can compare the major dosing references side by side.

Result: Use the adjusted body weight as the protocol review value, then confirm the final medication dose against the current dosing guideline.

Frequently Asked Questions

What is adjusted body weight and when is it used?

Adjusted body weight (ABW) is a pharmacokinetic parameter calculated to provide a more appropriate weight for drug dosing in obese patients. It accounts for the fact that excess adipose tissue has different drug distribution properties compared to lean tissue. The formula is ABW = IBW + adjustment factor multiplied by (actual weight minus IBW). The standard adjustment factor is 0.4, meaning approximately 40% of excess body weight is considered pharmacologically active. ABW is commonly used for dosing aminoglycosides, certain anticoagulants, and other medications where using actual body weight would result in overdosing and using ideal body weight would result in underdosing.

How is ideal body weight calculated?

Ideal body weight (IBW) is most commonly calculated using the Devine formula, which was originally developed in 1974 for drug dosing rather than as a health target. For males, IBW equals 50 kilograms plus 2.3 kilograms for each inch of height over 60 inches (5 feet). For females, IBW equals 45.5 kilograms plus 2.3 kilograms for each inch over 60 inches. This formula has limitations, particularly for very short or very tall individuals, as it can produce unrealistic values. Alternative formulas such as the Robinson, Miller, and Hamwi equations exist but the Devine formula remains the most widely used in clinical pharmacology. IBW does not represent an ideal health weight but rather a standardized reference for medication dosing.

What is the difference between IBW, ABW, and lean body weight?

These three weight parameters serve different clinical purposes and are calculated differently. Ideal body weight (IBW) is a height-based formula estimate that does not account for actual body composition, used primarily for ventilator tidal volume calculations and some drug dosing. Adjusted body weight (ABW) bridges the gap between IBW and actual weight by adding a fraction (typically 40%) of excess weight to IBW, used for dosing drugs like aminoglycosides in obese patients. Lean body weight (LBW) estimates the mass of everything except fat tissue, including muscle, bone, organs, and water, calculated using formulas like the Boer or James equations. LBW is useful for dosing propofol and other anesthetic agents. Each metric has specific clinical applications and no single weight parameter is appropriate for all medications.

Which drugs should be dosed using adjusted body weight?

Several medication classes benefit from adjusted body weight dosing in obese patients. Aminoglycosides (gentamicin, tobramycin, amikacin) are the most well-studied, with ABW dosing producing target peak and trough levels more reliably than either actual or ideal body weight. Enoxaparin for venous thromboembolism treatment in morbidly obese patients is sometimes dosed using ABW, though evidence is evolving. Loading doses of heparin may use ABW in severely obese patients. Some institutions use ABW for acyclovir dosing in obese patients with herpes infections. The critical principle is that highly water-soluble (hydrophilic) drugs with narrow therapeutic indices benefit most from ABW dosing because their distribution into fat is limited but not negligible.

When should actual body weight be used instead of adjusted weight?

Actual body weight (ABW) is appropriate for dosing several important medications even in obese patients. Vancomycin should be dosed using actual body weight because its volume of distribution correlates closely with total body mass, and underdosing leads to treatment failure and resistance. Unfractionated heparin initial bolus dosing typically uses actual weight with close aPTT monitoring. Most chemotherapy protocols use actual body weight or body surface area calculated from actual weight, as dose reductions in obese patients have been associated with worse outcomes. Loading doses of highly lipophilic drugs like amiodarone may also use actual weight. The decision depends on the specific drug properties, available evidence, and institutional protocols. When in doubt, therapeutic drug monitoring should guide dosing adjustments.

How does BMI relate to drug dosing decisions?

BMI serves as the primary trigger for switching from standard weight-based dosing to alternative dosing strategies. Generally, patients with BMI greater than 30 should have their dosing weight carefully considered rather than defaulting to actual body weight. At BMI 30-35, the difference between actual and ideal body weight may be modest and standard dosing may still be acceptable for many drugs. At BMI 35-40, adjusted body weight becomes increasingly important for drugs with narrow therapeutic indices. At BMI greater than 40 (morbid obesity), the discrepancy between actual and ideal body weight is substantial, and using actual weight for hydrophilic drugs risks significant overdosing. BMI also affects drug absorption from subcutaneous injections and may influence bioavailability of oral medications through altered gastrointestinal transit and metabolism.